Imugene Limited (ASX:IMU) scientific advisor Professor Ursula Wiedermann is to present on the company’s HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 annual meeting.
Wiedermann is the co-inventor of HER-Vaxx and also a member of Imugene’s scientific advisory board.
The presentation is authored by Wiedermann and researchers at the Medical University of Vienna in Australia and Imugene.
Its title is ‘A phase1b open label multi-centre study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/neu overexpressed advanced cancer of the stomach.
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
The immunotheraphy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.
It has been show in pre-clinical studies and phase-one studies to stimulate a potent polyclonal antibody response to HER2/neu, a well-known and validated cancer target.
The company recently had its phase-one clinical trial data for its B cell cancer vaccine B-Vaxx published in the prestigious AACR journal Clinical Cancer Research.
The article was primarily authored by Imugene’s scientific advisory board members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.